新冠病毒病前后的间质性肺疾病：双重威胁？
Interstitial lung disease before and after COVID-19: a double threat?
作者信息
Valenzuela Claudia, Waterer Grant, Raghu Ganesh
机构信息
ILD Unit, Pulmonology Dept Hospital Universitario de la Princesa, University Autonoma de Madrid, Madrid, Spain.
University of Western Australia, Royal Perth Hospital, Perth, Australia.
出版信息
Eur Respir J. 2021 Dec 2;58(6). doi: 10.1183/13993003.01956-2021. Print 2021 Dec.
Abstract
摘要
https://bit.ly/3jWBPCG （这是一个链接，无法准确翻译其内容，保留原文链接形式）
相似文献
1
Interstitial lung disease before and after COVID-19: a double threat?新冠病毒病前后的间质性肺疾病：双重威胁？
Eur Respir J. 2021 Dec 2;58(6). doi: 10.1183/13993003.01956-2021. Print 2021 Dec.
2
COVID-19 pneumonia can cause irreversible lung damage in dermatomyositis with pre-existing interstitial lung disease.新冠病毒肺炎可在已有间质性肺病的皮肌炎患者中导致不可逆的肺损伤。
Int J Rheum Dis. 2021 Sep;24(9):1221-1223. doi: 10.1111/1756-185X.14204. Epub 2021 Aug 9.
3
Post-COVID Interstitial Lung Disease-The Tip of the Iceberg.新冠后间质性肺病——冰山一角。
Immunol Allergy Clin North Am. 2023 May;43(2):389-410. doi: 10.1016/j.iac.2023.01.004. Epub 2023 Mar 3.
4
Persistent pulmonary disease after acute covid-19.新型冠状病毒肺炎（COVID-19）急性感染后持续性肺部疾病
BMJ. 2021 Jun 21;373:n1565. doi: 10.1136/bmj.n1565.
5
Eliciting History of Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Diagnosing Interstitial Lung Disease during the Coronavirus Disease 2019 Pandemic.在2019冠状病毒病大流行期间诊断间质性肺疾病时获取既往严重急性呼吸综合征冠状病毒2感染史
Chest. 2021 Mar;159(3):1306. doi: 10.1016/j.chest.2020.10.028.
6
Contemporary Concise Review 2021: Interstitial lung disease.当代简明综述 2021：间质性肺疾病。
Respirology. 2022 Jul;27(7):539-548. doi: 10.1111/resp.14278. Epub 2022 May 5.
7
Post-COVID Interstitial Lung Disease - The Looming Epidemic.新冠后间质性肺病——即将到来的流行病。
J Assoc Physicians India. 2021 Jul;69(7):11-12.
8
Prevalence of post-COVID symptoms one-year after SARS-CoV-2 infection in patients with interstitial lung disease.间质性肺疾病患者感染新型冠状病毒2年后新冠后遗症的患病率
Eur J Intern Med. 2024 May;123:161-162. doi: 10.1016/j.ejim.2024.01.039. Epub 2024 Feb 7.
9
Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic.COVID-19 大流行早期间质性肺疾病患者的单中心经验。
Respir Investig. 2020 Nov;58(6):437-439. doi: 10.1016/j.resinv.2020.08.006. Epub 2020 Sep 19.
10
Dermatomyositis-related interstitial lung disease mimicking COVID-19 pneumonia.皮肌炎相关的间质性肺疾病酷似新型冠状病毒肺炎。
Cleve Clin J Med. 2021 Sep 1;88(9):484-486. doi: 10.3949/ccjm.88a.20204.
引用本文的文献
1
Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.新冠疫苗接种的心肺效应：一篇全面的叙述性综述
Vaccines (Basel). 2025 May 22;13(6):548. doi: 10.3390/vaccines13060548.
2
Inequalities and age-period-cohort effects of global and regional burden for interstitial lung disease and pulmonary sarcoidosis: based on Global Burden of Disease study 2021.间质性肺疾病和结节病的全球及区域负担的不平等与年龄-时期-队列效应：基于《2021年全球疾病负担研究》
Front Med (Lausanne). 2025 May 26;12:1471402. doi: 10.3389/fmed.2025.1471402. eCollection 2025.
3
Active pulmonary interstitial fibrosis in a COVID-19 survivor diagnosed by transbronchial lung cryobiopsy six months after onset.一名新冠病毒疾病（COVID-19）幸存者在发病六个月后经支气管肺冷冻活检诊断为活动性肺间质纤维化。
Hum Pathol Rep. 2022 Sep;29:300666. doi: 10.1016/j.hpr.2022.300666. Epub 2022 Jun 27.
4
Loss of Lung Function Led to Loss of Life during the COVID-19 Pandemic.在新冠疫情期间，肺功能丧失导致了生命丧失。
Am J Respir Crit Care Med. 2025 Jul;211(7):1114-1115. doi: 10.1164/rccm.202503-0695ED.
5
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.吡非尼酮治疗新冠后肺纤维化（FIBRO-COVID）：一项2期随机临床试验
Eur Respir J. 2025 Apr 24;65(4). doi: 10.1183/13993003.02249-2024. Print 2025 Apr.
6
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease.2022 年肺功能更新和 GLI 全球参考方程对间质性肺疾病患者的影响。
Thorax. 2024 Oct 16;79(11):1024-1032. doi: 10.1136/thorax-2024-221813.
7
Long-Term Effects of COVID-19 on the Cardiopulmonary System in Adults and Children: Current Status and Questions to be Resolved by the National Institutes of Health Researching COVID to Enhance Recovery Initiative.成人和儿童 COVID-19 对心肺系统的长期影响：美国国立卫生研究院 COVID 增强康复研究倡议研究的现状和待解决的问题。
Chest. 2024 Apr;165(4):978-989. doi: 10.1016/j.chest.2023.12.030. Epub 2024 Jan 6.
8
Risk of 30-Day All-Cause Readmission in Interstitial Lung Disease Patients after COVID-19: National-Level Data.COVID-19 后间质性肺病患者 30 天全因再入院风险：全国水平数据。
Ann Am Thorac Soc. 2024 Mar;21(3):428-437. doi: 10.1513/AnnalsATS.202305-491OC.
9
Silico-tuberculosis amidst COVID-19 pandemic: global scenario and Indian perspective.新冠疫情期间的硅肺结核：全球形势与印度视角
Ann Med Surg (Lond). 2023 Nov 1;85(12):6083-6090. doi: 10.1097/MS9.0000000000001471. eCollection 2023 Dec.
10
Longitudinal Analysis of Pulmonary Function Impairment One Year Post-COVID-19: A Single-Center Study.新冠病毒感染后一年肺功能损害的纵向分析：一项单中心研究
J Pers Med. 2023 Jul 26;13(8):1190. doi: 10.3390/jpm13081190.
本文引用的文献
1
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.托法替布治疗因 COVID-19 肺炎住院的患者。
N Engl J Med. 2021 Jul 29;385(5):406-415. doi: 10.1056/NEJMoa2101643. Epub 2021 Jun 16.
2
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.COVID-19 相关住院患者的 3 个月、6 个月、9 个月和 12 个月呼吸结局：一项前瞻性研究。
Lancet Respir Med. 2021 Jul;9(7):747-754. doi: 10.1016/S2213-2600(21)00174-0. Epub 2021 May 5.
3
Interstitial lung disease increases susceptibility to and severity of COVID-19.间质性肺疾病增加了感染 COVID-19 的易感性和严重程度。
Eur Respir J. 2021 Dec 2;58(6). doi: 10.1183/13993003.04125-2020. Print 2021 Dec.
4
Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia.重症 COVID-19 肺炎患者 6 个月随访的胸部 CT 结果。
Radiology. 2021 Apr;299(1):E177-E186. doi: 10.1148/radiol.2021203153. Epub 2021 Jan 26.
5
Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.持续性 COVID-19 间质性肺病。皮质类固醇治疗的观察性研究。
Ann Am Thorac Soc. 2021 May;18(5):799-806. doi: 10.1513/AnnalsATS.202008-1002OC.
6
Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial "impact" beyond any expectation.希腊早期的新冠疫情封锁与特发性肺纤维化：超乎预期的有益“影响”。
Eur Respir J. 2021 Mar 25;57(3). doi: 10.1183/13993003.03111-2020. Print 2021 Mar.
7
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
8
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19.COVID-19 住院 3 个月后的呼吸困难、肺功能和 CT 表现。
Eur Respir J. 2021 Apr 29;57(4). doi: 10.1183/13993003.03448-2020. Print 2021 Apr.
9
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial.COVID-19 后心肺功能的恢复：一项观察性前瞻性多中心试验。
Eur Respir J. 2021 Apr 29;57(4). doi: 10.1183/13993003.03481-2020. Print 2021 Apr.
10
Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease.患有间质性肺疾病的COVID-19患者死亡的危险因素
Am J Respir Crit Care Med. 2021 Jan 15;203(2):245-249. doi: 10.1164/rccm.202007-2638LE.
Zotero 插件